Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management
S Sukumar, B Lämmle, SR Cataland - Journal of clinical medicine, 2021 - mdpi.com
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy
characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and …
characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and …
Shiga toxin-associated hemolytic uremic syndrome: A narrative review
A Joseph, A Cointe, P Mariani Kurkdjian, C Rafat… - Toxins, 2020 - mdpi.com
The severity of human infection by one of the many Shiga toxin-producing Escherichia coli
(STEC) is determined by a number of factors: the bacterial genome, the capacity of human …
(STEC) is determined by a number of factors: the bacterial genome, the capacity of human …
[HTML][HTML] The ADAMTS13‐von Willebrand factor axis in COVID‐19 patients
I Mancini, L Baronciani, A Artoni, P Colpani… - Journal of Thrombosis …, 2021 - Elsevier
Background Severe coronavirus disease 2019 (COVID‐19) is characterized by an increased
risk of thromboembolic events, with evidence of microthrombosis in the lungs of deceased …
risk of thromboembolic events, with evidence of microthrombosis in the lungs of deceased …
[HTML][HTML] ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura
Background Despite an increase in our understandings of pathogenesis of thrombotic
thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of …
thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management of …
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura
Background In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated
deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained …
deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained …
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP
The anti–von Willebrand factor nanobody caplacizumab was licensed for adults with
immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective …
immune-mediated thrombotic thrombocytopenic purpura (iTTP) based on prospective …
Redefining outcomes in immune TTP: an international working group consensus report
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal
thrombotic microangiopathy caused by autoantibody-mediated severe deficiency of …
thrombotic microangiopathy caused by autoantibody-mediated severe deficiency of …
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
LA Völker, J Kaufeld, W Miesbach, S Brähler… - Blood …, 2020 - ashpublications.org
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening
condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults …
condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults …
Clinical and laboratory diagnosis of TTP: an integrated approach
T Chiasakul, A Cuker - Hematology 2014, the American Society …, 2018 - ashpublications.org
Thrombotic thrombocytopenia purpura (TTP) is a rare, life-threatening disease with an
incidence of approximately 2 persons per million per year. It is characterized by severe …
incidence of approximately 2 persons per million per year. It is characterized by severe …
Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura
Background Congenital thrombotic thrombocytopenic purpura (TTP) results from severe
hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and …
hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and …